The Schall Law Firm Initiates Examination Into Relmada Therapeutics Inc For Potential Securities Breaches And Encourages Impacted Investors To Establish ContactAccesswire • 07/05/24
The Schall Law Firm Investigates Relmada Therapeutics Inc For Potential Securities Breaches And Encourages Impacted Investors To ConnectAccesswire • 07/03/24
The Schall Law Firm Probes Relmada Therapeutics Inc For Possible Securities Violations And Urges Affected Investors To ContactAccesswire • 07/02/24
The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Infringements Of Securities Regulations And Encourages Investors Who Experienced Losses To Make ContactAccesswire • 06/28/24
The Schall Law Firm Is Probing Relmada Therapeutics Inc For Possible Breaches Of Securities Laws And Urges Investors Who Sustained Losses To Reach OutAccesswire • 06/27/24
The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Law Violations And Encourages Investors With Losses To ContactAccesswire • 06/25/24
The Schall Law Firm Is Probing Relmada Therapeutics Inc For Possible Securities Law Breaches And Urges Investors Who Incurred Losses To Reach OutAccesswire • 06/24/24
Potential Violations Of Securities Laws By Relmada Therapeutics Inc Are Being Investigated By The Schall Law Firm Investors Who Have Suffered Losses Are Encouraged To Connect With The FirmAccesswire • 06/23/24
Possible Breaches Of Securities Laws By Relmada Therapeutics Inc Are Being Probed By The Schall Law Firm Investors With Financial Losses Are Invited To Reach Out To The FirmAccesswire • 06/22/24
Potential Violations Of Securities Laws By Relmada Therapeutics Inc Are Under Investigation By The Schall Law Firm Investors Who Have Incurred Financial Losses Are Encouraged To Contact The FirmAccesswire • 06/19/24
The Schall Law Firm Is Probing Potential Securities Breaches By Relmada Therapeutics Inc Investors With Monetary Losses Are Urged To Reach Out To The FirmAccesswire • 06/18/24
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical PsychiatryPRNewsWire • 06/18/24
Relmada Therapeutics Inc. (NASDAQ: RLMD) Under Investigation By Schall Law Firm For Potential Securities Violations. Investors Who Lost Money Encouraged To Contact The FirmAccesswire • 06/17/24
Claims Against Relmada Therapeutics, Inc.: Schall Law Firm Starts Investigation And Invites Affected Investors To Get In TouchAccesswire • 06/11/24
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferencePRNewsWire • 06/10/24
Accusations Made Against Relmada Therapeutics, Inc.: Schall Law Firm Commences Probe And Calls On Impacted Investors To ParticipateAccesswire • 06/09/24
Charges Leveled At Relmada Therapeutics, Inc.: Schall Law Firm Begins Investigation And Invites Impacted Investors To Engage.Accesswire • 06/08/24
Accusations Against Relmada Therapeutics, Inc.: Schall Law Firm Initiates Probe And Calls On Impacted Investors To ConnectAccesswire • 06/07/24
Allegations Against Relmada Therapeutics, Inc.: Schall Law Firm Starts Investigation and Urges Impacted Investors to Reach OutAccesswire • 06/06/24
Relmada Therapeutics, Inc. Allegations: Schall Law Firm Initiates Inquiry and Invites Affected Investors to ConnectAccesswire • 06/05/24
The Schall Law Firm is Initiating an Inquiry into Allegations Against Relmada Therapeutics, Inc. and is Inviting Investors who Have Incurred Losses to Reach OutAccesswire • 06/04/24
RLMD CRUCIAL INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 06/03/24
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare ConferencePRNewsWire • 06/03/24
INVESTIGATION PROGRESS UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 06/02/24
INVESTIGATION PROGRESS REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 06/02/24